Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab Combined With Chidamide in Relapsed/Refractory CTCL
NCT04296786Phase 2Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Nov 2019
- Primary completion
- Dec 2022
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab, tucidinostat in cutaneous T-cell lymphoma (CTCL), sponsored by Peking Union Medical College Hospital. Status: unknown.
02
Drugs
sintilimabtucidinostat
03
Conditions
cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT04296786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04296786.